Aprogen에이프로젠
007460 · KOSPI · ₩007460 · 에이프로젠
₩1,940▲ ₩26 (1.36%)End-of-day · Oct 28, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 26.6% | 28.2% | 23.3% | 23.8% | 7.9% | 22.1% |
| Operating margin | −66.4% | −81.0% | −57.8% | −59.0% | −152.3% | −1.9% |
| Net margin | −60.1% | −59.5% | −38.7% | −36.9% | −125.9% | −12.7% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +17.7% | −21.4% | −0.3% | +92.2% | −44.5% | — |
| Operating income growth | +3.5% | −10.1% | +2.3% | +25.5% | −4,366.0% | — |
| Net income growth | −19.0% | −20.9% | −4.4% | +43.6% | −448.0% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −76.3% | −44.3% | −37.9% | −30.7% | −35.8% | −5.4% |
| Return on assets | −20.2% | −21.2% | −16.7% | −16.3% | −16.3% | −1.5% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 62.8% | 56.4% | 38.6% | 42.3% | 30.1% | 17.0% |
| Net debt to equity | 34.3% | 30.7% | 17.2% | 21.0% | 9.9% | 2.2% |
| Current ratio | 83.5% | 97.2% | 118.9% | 114.8% | 235.3% | 437.3% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Aprogen / 에이프로젠 / 007460 / KRX:007460
Source: KRX statistical information